I asked Leo about the invite and expenses for the Nov.IBD
I asked Leo about the invite and expenses for the Nov.IBD conference and he said the foundation invited IPIX and there will be no expenses for them to attend and present either.
Talking with Petemantx about yesterday's PR and he had some very great thoughts about it so I'm sharing them here as well.
Kelt
"My take as to today's PR:
Made perfect sense in the way of starting to put out PRs to get eyes looking our way but not giving away anything regarding the milestones yet.
It was part of Leo's strategy to make the most of the main news coming later in the month.
I never thought the Brilacidin platform would be sold or partnered in it's entirety this early in the game as there is not nearly enough known about it yet to be able to predict the widespread uses it should hold. I thought Dr. B made a statement that we hadn't even scratched the surface yet of what it should be able to do. IBD indication never has been on the table IMO and won't be until we get a pill formulation and that formulation should be based on ph level so that the pill will work exactly where desired in the GI tract to pinpoint the treatment for Crohn's Disease, UC, UCS, etc. Until then, we won't get anywhere near the valuation for B that it deserves as I believe it should rival Humira in revenues when all is said and done.
OM is the indication in play based on the Evonik/CoreRx contracts and the fact that because it is a swish-and-spit formulation the partner could not infringe on all the other B indications as they will have to be addressed thru topical creams (dermatology indications) or pill (IBD indications) and whatever else B is found to do will not be addressed thru swish and spit.
Besides OM, which I believe may bring double digit $MM upfront payment, the other indication may be Prurisol for psoriasis only. If/When we get the expected great P2b results, we should see very decent double digit $MM upfront payment or higher. Again, the dermatology indications for Prurisol will most likely be via topical creams so no crossover problems. Don't know yet about the other autoimmune disease indications but we should allow the psoriasis partner to have last right of bidding for all other autoimmune disease indications as this would really increase the upfront bidding for the psoriasis indication IMO.
I don't see a timing problem w/ this PR as I never expected or wanted the entire B platform to be on the sale block now nor a sale of the whole company as both would be far, far too low compared to what they will bring within a year to 18 months. I prefer to wait for that time to think about selling a total platform.
K platform again cannot be partnered out until the pill formulation is completed for the same reason, too low a value at this time, especially if we then go thru a very fast trial just to get physio-kinetic data as to safety and good idea of how fast it leaves the body.
So IMO Leo's P2b and BTD milestones are a lock already as I believe they have the BTD and are sitting on the announcement. That makes Leo's only major goal RIGHT NOW to be signing a deal to bring in double digit cash now to provide us with needed funds to further advance all drug platforms. I believe this PR helps light a fire under all the BPs that are serious suitors to get such a deal for an indication by end of Sept. "
8
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Johannesburg’s AI conversation seems to be shedding its costume jewelry at last. Zensar’s invitation-only CIS Converge 2026 forum, held on November 20, put the attention where it belongs: not on breathless demos, but on whether companies can turn AI into sturdier operations, better customer experiences, and something resembling a measurable return. That is a healthier...
Continue Reading
Three ugly selloffs, a murky land-bank story, and a fresh securities complaint have turned Lennar into the sort of holding that makes shareholders reread every footnote. The lawsuit is not a verdict, and the allegations remain unproven, but the timeline is nasty enough that investors in NYSE:LEN should not shrug it off as ordinary housing-cycle turbulence. The Dates...
Continue Reading
Private-market paperwork has long been a swamp of portals, PDFs, email chains, and somebody chasing down a wire change at the worst possible moment. Anduin is taking a swing at that mess by opening its Investor Portal to all customers after building it with leading asset managers and operating it with their investors. The pitch is sensible: give limited partners one...
Continue Reading
A fish, a kilowatt-hour, a microchip, and a shipping container walk into the same economic story—well, not literally, thank goodness—and that is the unusual wager behind CCTV4’s upcoming Our Home, Our Yangtze. Announced in Beijing on November 19, 2026, the four-part documentary aims to recount a decade of change across the Yangtze River Economic Belt without leaning...
Continue Reading
A Narrow Calendar Window Has Opened Intel holders have another legal deadline to put on the fridge, and this one is not a casual housekeeping item. A securities class action has been filed in the Northern District of California on behalf of investors who bought or acquired Intel shares between July 23, 2026, and October 29, 2026. The deadline to seek appointment as lead...
Continue Reading
Personalized cancer vaccines have no shortage of grand promises; seasoned clinical operators are the rarer commodity. That is why BreakBio's appointment of Dr. Greg Lizée as chief scientific officer deserves a closer look, even if nobody should confuse an executive hire with clinical validation. BreakBio is private, its lead program remains in development, and cancer...
Continue Reading
Spreadsheets breed little kingdoms, and SAP is often left outside the gate. That is the operational mess Martin Rowan, managing partner at Reveal USA, Inc. in Naperville, is taking aim at in a Nov. 19, 2026 HelloNation feature. His central point is not terribly glamorous, but it is dead right: a company gets less stable when it uses SAP to explain yesterday's results...
Continue Reading
Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...
Continue Reading
Retail’s front door is quietly being moved by a machine, and plenty of big chains appear to be staring at the old entrance. Bain’s latest work lands on an uncomfortable point: owning market share does not guarantee a retailer gets named when an AI assistant answers a shopper’s question. That ought to rattle management teams more than the usual holiday-season...
Continue Reading
A Quiet Vendor Failure Can Become a Loud Problem Tax files are not ordinary customer records, and that is why this reported Baker Tilly Advisory Group breach deserves more than the usual shrug people give cyber incidents. Names and addresses are bad enough; the potential exposure of Social Security numbers and other sensitive information turns a systems failure into a...
Continue Reading
Top 5 Most Recently Viewed Articles
Eagle Pharmaceuticals Board Extends Rights Plan Duration Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) has announced an update regarding its stockholder rights plan. The Board of Directors has approved an important amendment to the existing limited duration rights plan, extending its validity for one additional year, until October 30, 2026. Reason for the Amendment This...
Continue Reading
Trump's Immigration Policies and Economic Growth Donald Trump's approach to immigration is likely to influence the rate of migration into the United States significantly, implying a potential slowdown in the nation's economic growth. Analysts at Piper Sandler have expressed concerns that the upcoming policies could lead to a meaningful deceleration in migration rates that...
Continue Reading
Sonder Holdings Faces Nasdaq Compliance Challenges Sonder Holdings Inc. (NASDAQ: SOND), a cutting-edge hospitality company known for its tech-enhanced accommodations, recently received a formal notification from Nasdaq regarding a compliance issue. This is primarily due to the company's delay in filing its Q3 financial report for the period ending September 30, 2024. The...
Continue Reading
Overview of the 2024 AvaSure Symposium Healthcare professionals from across the country are preparing to convene for the 2024 AvaSure Symposium. This event will focus on the significant impact of AI-driven virtual care platforms on improving patient outcomes, enhancing staff satisfaction, and ensuring a healthy return on investment (ROI). Event Information The upcoming...
Continue Reading
Revolutionizing Scientific Communication: Stempad's Winter Update Stempad, the world's first alternative for pen-and-paper scientific writing, has excited the academic community with the announcement of its new winter features. This innovative tool supports students, educators, and researchers in STEM fields, ensuring they have a seamless solution for effective scientific...
Continue Reading